Antineutrophil cytoplasm autoantibodies in patients with tuberculosis are directed against bactericidal/permeability increasing protein and are detected after treatment initiation

Clin Exp Rheumatol. 2010 Jan-Feb;28(1 Suppl 57):35-9.

Abstract

Objectives: To determine the prevalence of antineutrophil cytoplasm autoantibodies (ANCA) and its antigenic specificities in sera of patients with pulmonary tuberculosis (Tb) before and after treatment.

Patients and methods: Sixty-eight patients with culture-proven Tb were studied for the presence of ANCA, both by indirect immunofluorescence (IIF) and ELISA against proteinase-3 (PR3), myeloperoxidase (MPO) and bactericidal/permeability increasing protein (BPI). They were sought before treatment and in 52 of them also after therapy for the infection. High sensitivity C-reactive protein (CRP) was also measured at both times.

Results: ANCA by IIF were found in 3/68 (4.4%) sera prior to treatment, one C-ANCA and two P-ANCA, all recognizing BPI. After treatment, this increased to 15/52 (28.8%), 3 C-ANCA and 12 P-ANCA, the majority directed against BPI (11/15, 73%). BPI-ANCA were positive in 6/68 (8.8%) and 15/52 (28.8%) before and after Tb after treatment initiation (p=0.003). PR3-ANCA and MPO-ANCA were negative in all Tb sera. A positive ANCA test correlated with CRP as inflammatory marker (p=0.001).

Conclusions: The prevalence of ANCA in culture positive Tb patients is modified by Tb chemotherapy. BPI is the main target antigen for ANCA in tuberculosis and BPI-ANCA increase after treatment.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Antineutrophil Cytoplasmic / blood*
  • Antimicrobial Cationic Peptides / immunology*
  • Antitubercular Agents / therapeutic use*
  • Blood Proteins / immunology*
  • Enzyme-Linked Immunosorbent Assay
  • Epitopes
  • Female
  • Fluorescent Antibody Technique, Indirect
  • Humans
  • Male
  • Middle Aged
  • Myeloblastin / immunology
  • Peroxidase / immunology
  • Seroepidemiologic Studies
  • Tuberculosis, Pulmonary* / drug therapy
  • Tuberculosis, Pulmonary* / epidemiology
  • Tuberculosis, Pulmonary* / immunology

Substances

  • Antibodies, Antineutrophil Cytoplasmic
  • Antimicrobial Cationic Peptides
  • Antitubercular Agents
  • Blood Proteins
  • Epitopes
  • bactericidal permeability increasing protein
  • Peroxidase
  • Myeloblastin